journal article·2022-07

Versatile Protein Coronation Approach with Multiple Depleted Serum for Creating Biocompatible, Precision Nanomedicine

Chan Wang, Mengdie Xue, Xiao Liu, Jingjing Chen, Mengdie Jiang, Liuting Zheng, Ruxuan Ma, Chengjin Ding, Yaping Tao, Hao Zhang, Qin Liu, Da Huo

Small· Volume 18· Issue 30
Publisher page

Abstract

Abstract The protein corona effect has long been treated as the evil source behind delivery efficacy issues. In this study, this concept is challenged by showcasing that the protein corona can serve as a versatile functionalization approach to improve the delivery efficacy or mitigate nanocytotoxicity. To this end, the depleted serum is introduced to create nanomaterials carrying functionally distinct protein corona, referred to as PCylated nanomaterials. It is confirmed that the passivation with depleted serum helps reduce the toxicity and pro‐inflammatory response. Furthermore, the same method can be leveraged to enhance the capacity of nanomaterials to undergo endocytosis as well as their potential as an agonist for the NF‐κB pathways. The comparable stability of protein corona created by late and early‐stage serum reveals that the chanceless interaction with nanomaterials, rather than an inadequate binding strength, may be behind the failure of enriching certain components. The PCylation strategy is extended to cancer patient‐derived fluid, creating a set of T1 and T3‐stage cancer‐specific nanotherapeutics to retard the metastasis of cancer cells, while leaving normal endothelial negligibly affected. It is hoped the novel PCylation approach validated here can shed light on the future development of precision nanomedicine with improved delivery efficacy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medicinal Chemistry Key Laboratory of Cardiovascular and Cerebrovascular Medicine School of Pharmacy Nanjing Medical University Nanjing 211166 P. R. China

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University No. 321, Zhongshan Road Nanjing 210008 P. R. China

Department of Oncology the First Affiliated Hospital with Nanjing Medical University Nanjing 210029 P. R. China

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University No. 321, Zhongshan Road Nanjing 210008 P. R. China

Funding

National Natural Science Foundation of China · Nanjing Medical University · Natural Science Research of Jiangsu Higher Education Institutions of China

References (70)

Show source-provided references
1. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
2. 10.1073/pnas.060858210410.1073/pnas.0608582104 ↗
3. 10.1021/nn901372t10.1021/nn901372t ↗
4. 10.1038/nnano.2009.24810.1038/nnano.2009.248 ↗
5. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
6. 10.1038/s41467-017-00600-w10.1038/s41467-017-00600-w ↗
7. 10.1002/adfm.20170195610.1002/adfm.201701956 ↗
8. 10.1038/nnano.2015.33010.1038/nnano.2015.330 ↗
9. 10.1039/C8NR00835C10.1039/C8NR00835C ↗
10. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
11. 10.3389/fimmu.2020.56736510.3389/fimmu.2020.567365 ↗
12. 10.1038/s41467-019-12470-510.1038/s41467-019-12470-5 ↗
13. 10.1002/smll.20190757410.1002/smll.201907574 ↗
14. 10.1021/acs.langmuir.5b0215810.1021/acs.langmuir.5b02158 ↗
15. 10.1021/acsnano.1c0768710.1021/acsnano.1c07687 ↗
16. 10.1002/ppsc.20130025610.1002/ppsc.201300256 ↗
17. 10.1002/adfm.20100165810.1002/adfm.201001658 ↗
18. 10.1002/adfm.20170730910.1002/adfm.201707309 ↗
19. 10.1016/S0939-6411(02)00081-410.1016/S0939-6411(02)00081-4 ↗
20. 10.1021/ja208433810.1021/ja2084338 ↗
21. 10.1182/blood.V55.1.156.15610.1182/blood.V55.1.156.156 ↗
22. 10.1002/adfm.20160203610.1002/adfm.201602036 ↗
23. 10.1098/rsif.2009.0272.focus10.1098/rsif.2009.0272.focus ↗
24. 10.1021/acs.biomac.7b0147210.1021/acs.biomac.7b01472 ↗
25. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
26. 10.1146/annurev.immunol.021908.13255710.1146/annurev.immunol.021908.132557 ↗
27. 10.1038/nri307310.1038/nri3073 ↗
28. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗
29. 10.1039/C8SC01828F10.1039/C8SC01828F ↗
30. 10.1002/adfm.20170183710.1002/adfm.201701837 ↗
31. 10.3390/nano503116310.3390/nano5031163 ↗
32. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
33. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
34. 10.1002/adfm.20100046110.1002/adfm.201000461 ↗
35. 10.1016/j.jconrel.2018.01.00210.1016/j.jconrel.2018.01.002 ↗
36. 10.1039/D0CS01127D10.1039/D0CS01127D ↗
37. 10.1038/s41580-021-00375-510.1038/s41580-021-00375-5 ↗
38. 10.1016/j.tibs.2020.03.01010.1016/j.tibs.2020.03.010 ↗
39. 10.1016/j.jconrel.2010.11.00410.1016/j.jconrel.2010.11.004 ↗
40. 10.1016/j.biomaterials.2019.05.00210.1016/j.biomaterials.2019.05.002 ↗
41. 10.1038/s41416-020-01179-810.1038/s41416-020-01179-8 ↗
42. 10.7150/thno.3890010.7150/thno.38900 ↗
43. 10.2217/nnm-2018-032610.2217/nnm-2018-0326 ↗
44. 10.1007/s00018-020-03523-w10.1007/s00018-020-03523-w ↗
45. 10.1126/science.aba377110.1126/science.aba3771 ↗
46. 10.1161/CIRCRESAHA.116.30285510.1161/CIRCRESAHA.116.302855 ↗
47. 10.1039/C5CS00499C10.1039/C5CS00499C ↗
48. 10.1016/j.jconrel.2014.03.00610.1016/j.jconrel.2014.03.006 ↗
49. 10.1152/physrev.00035.200310.1152/physrev.00035.2003 ↗
50. 10.1039/C7CS00511C10.1039/C7CS00511C ↗
51. 10.32350/sir/2020/43/98110.32350/sir/2020/43/981 ↗
52. 10.1038/nrm136810.1038/nrm1368 ↗
53. 10.1002/smll.20190760910.1002/smll.201907609 ↗
54. 10.1016/j.gendis.2020.06.00510.1016/j.gendis.2020.06.005 ↗
55. 10.1021/acs.bioconjchem.9b0084710.1021/acs.bioconjchem.9b00847 ↗
56. 10.1021/acs.nanolett.9b0177410.1021/acs.nanolett.9b01774 ↗
57. 10.1038/s41577-021-00524-z10.1038/s41577-021-00524-z ↗
58. 10.1038/s41580-020-0244-x10.1038/s41580-020-0244-x ↗
59. 10.1016/j.coi.2022.01.00410.1016/j.coi.2022.01.004 ↗
60. 10.1002/mabi.20210013310.1002/mabi.202100133 ↗
61. 10.3322/caac.2160110.3322/caac.21601 ↗
62. 10.1002/adfm.20200032610.1002/adfm.202000326 ↗
63. 10.1002/jcp.2702710.1002/jcp.27027 ↗
64. 10.4048/jbc.2018.21.e5110.4048/jbc.2018.21.e51 ↗
65. 10.1002/smll.20200028510.1002/smll.202000285 ↗
66. 10.1038/s41467-020-16772-x10.1038/s41467-020-16772-x ↗
67. 10.1038/s41565-021-00924-110.1038/s41565-021-00924-1 ↗
68. 10.1002/smll.20190757410.1002/smll.201907574 ↗
69. 10.1016/bs.mie.2019.10.00510.1016/bs.mie.2019.10.005 ↗
70. 10.1038/s41467-020-18237-710.1038/s41467-020-18237-7 ↗